# Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo

> **NCT00434967** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 2207 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Candesartan cilexetil
- **DRUG:** Hydrochlorothiazide
- **DRUG:** Candesartan/HCT 32/25 mg

## Key facts

- **NCT ID:** NCT00434967
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 2207 (ACTUAL)
- **Last updated:** 2010-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00434967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00434967, "Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00434967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*